NEW YORK, NY / ACCESSWIRE / September 15, 2022 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.

Enochian BioSciences, Inc. ENOB

If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/enochian-biosciences-inc-loss-submission-form?prid=31814&wire=1
Lead Plaintiff Deadline: September 26, 2022
Class Period: January 17, 2018 - June 27, 2022

Allegations against ENOB include that: (1) the Company's co-founder and inventor Serhat Gumrukcu was engaged in a variety of frauds; (2) Gumrukcu was not a licensed doctor anywhere in the world; (4) as a result of the foregoing, Gumrukcu's purported contributions to the Company lacked a reasonable basis; (5) as a result of the foregoing, the Company had overstated its commercial prospects; (6) Gumrukcu had improperly diverted approximately $20 million from Enochian to entities he owned; and (7) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

TuSimple Holdings Inc. TSP

If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/tusimple-holdings-class-action-loss-submission-form?prid=31814&wire=1
Lead Plaintiff Deadline: October 31, 2022
This lawsuit is on behalf of all persons who: (a) purchased or otherwise acquired TuSimple common stock pursuant and/or traceable to documents issued in connection with TuSimple's April 15, 2021 initial public offering; and/or (b) that purchased or otherwise acquired TuSimple securities between April 15, 2021 and August 1, 2022, both dates inclusive.

Allegations against TSP include that: (i) TuSimple's commitment to safety was significantly overstated and defendants concealed fundamental problems with the Company's technology; (ii) TuSimple was rushing the testing of its autonomous driving technology in order to deliver driverless trucks to the market ahead of its more safety-conscious competitors; (iii) there was a corporate culture within TuSimple that suppressed or ignored safety concerns in favor of unrealistically ambitious testing and delivery schedules; (iv) the aforementioned conduct made accidents involving the Company's autonomous driving technology more likely; (v) the aforementioned conduct invited enhanced regulatory scrutiny and investigatory action toward the Company; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Kohl's Corporation KSS

If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/kohls-lawsuit-loss-submission-form?prid=31814&wire=1
Lead Plaintiff Deadline: November 1, 2022
Class Period: October 20, 2020 - May 19, 2022

Allegations against KSS include that: (i) Kohl's new strategic framework to "drive top-line growth," "expand operating margin," and become "the most trusted retailer of choice for the active and casual lifestyle" (the "Strategic Plan") was not well tailored to achieving the Company's stated goals; (ii) the defendants had likewise overstated the Company's success in executing its Strategic Plan; (iii) Kohl's had deficient disclosure controls and procedures, internal control over financial reporting, and corporate governance mechanisms; (iv) as a result, the Company's board of directors was able to and did withhold material information from shareholders about the state of Kohl's in the lead-up to the Company's annual meeting; (v) all the foregoing, once revealed, was likely to have a material negative impact on Kohl's financial condition and reputation; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times.

To learn more contact Vincent Wong, Esq. either via email vw@wongesq.com or by telephone at 212.425.1140.

Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

SOURCE: The Law Offices of Vincent Wong

View source version on accesswire.com: